However, since 2015, Sanford has sent some of its U.S. patients to Isar Klinikum to receive stem cell therapies allowed in Germany. It has also sent 11 physicians to the hospital to learn more about these therapies.
Sanford Health President and CEO Kelby Krabbenhoft will serve as a member of Isar Klinik II AG’s board of directors.
“This is another significant step in our goal to advance health care around the world,” said Krabbenhoft. “Isar’s ground-breaking procedures and medical technology are well-known, and we are eager to strengthen our relationship with the hospital and its leaders to bring that knowledge and care to our patients.”
More articles on hospital transactions and valuations:
2 Kentucky hospitals sign acquisition agreement
Capital Health, LabCorp form laboratory partnership
Texas hospital looks to reopen under new management
